Deutsche Märkte öffnen in 20 Minuten

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
226,20-8,20 (-3,50%)
Börsenschluss: 04:00PM EST
227,00 +0,80 (+0,35%)
Nachbörse: 05:13PM EST

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200
https://www.alnylam.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter1.665

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Michael W. Bonney B.A.Exec. Chairman317,97kN/A1958
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChBCEO & Director1,23M6,7M1963
Dr. Akshay K. Vaishnaw M.D., Ph.D.Pres1,09M2,83M1963
Mr. Jeffrey V. Poulton M.B.A.CFO & Exec. VP914,05kN/A1968
Mr. Tolga Tanguler M.B.A.Exec. VP & Chief Commercial Officer875,86kN/AN/A
Dr. Alfred W. Boyle Ph.D.Chief Technical Operations & Quality OfficerN/AN/AN/A
Dr. Kevin Joseph Fitzgerald Ph.D.Sr. VP, Head of Research & Chief Scientific OfficerN/AN/A1968
Ms. Christine Regan LindenboomSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Indrani M. Lall Franchini J.D.Exec. VP, Chief Legal Officer & Sec.N/AN/A1972
Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Alnylam Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Oktober 2022, lautet 4. Die grundlegenden Scores sind Audit: 4, Vorstand: 4, Shareholderrechte: 6, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.